



CLEVIS T. PARKER, MD, MHA

505 E Windmill Lane Ste. C #167

Las Vegas, NV 89123

Cell: (325) 513-5778

drcparker@parker-medical.com

Award-winning hospice physician. Chief Executive Officer and Chief Medical Officer of ProCare Hospice of Nevada. Extensive expertise in hospice and palliative care medicine and regulatory/compliance issues. Double board certified. Active clinical practice. UNLV faculty.

PROFESSIONAL EXPERIENCE

ProCare Hospice of Nevada, Las Vegas, NV
Chief Executive Officer/Chief Medical Officer

September 2020 - Present

ProCare Hospice of Nevada, Las Vegas, NV
Chief Medical Officer

February 2020 - September 2020

Weatherbee Resources, Headland, AL
Consultant

January 2019 – Present

Nathan Adelson Hospice, Las Vegas, NV
Chief Medical Officer

January 2018 - January 2020

Hospice of Yuma, Yuma, AZ
Medical Director of Hospice Care

February 2016 - January 2018

Parkview Physician Group, Fort Wayne, IN
Physician Consultant

February 2016–December 2017

Parkview Physician Group, Fort Wayne, IN
Medical Director/Parkview Home & Health Hospice

February 2016–December 2017

Abilene Diagnostic Clinic, PLLC, Abilene, TX
Physician Family Medicine/Palliative Care

December 2010 – December 2013

Coronado Nursing Center, Abilene, TX
Medical Director Nursing Home

December 2010 – December 2013

Jones, Brown & Jones Health Care, LLC, Abilene, TX <u>Medical Director Home Health</u>	December 2010 – December 2013
Kindred HealthCare Operating, Inc., Louisville, KY <u>Medical Director Hospice/Palliative Care</u>	April 2012 – December 2013
Oceans Behavioral Hospital, Abilene, TX <u>Physician</u>	September 2013 – December 2013
Solaris Hospice, Decatur, TX <u>Medical Director Hospice/Palliative Care</u>	February 2011 – August 2011
Concerned Hospice, Covington, LA <u>Medical Director</u>	April 2010 – September 2010
Home Health Care 2000, Lake Charles, LA <u>Medical Director</u>	March 2010 – September 2010
Westbank Urgent Care, Gretna, LA <u>Physician</u>	December 2009 – December 2010
East Jefferson General Hospital, Metairie, LA <u>Physician Family Medicine/Palliative Care</u>	July 2009 – October 2010
Clinical Trials Management, LLC, Metairie, LA <u>Clinical Investigator</u>	December 2009 – October 2010
Vista Staffing Solutions, Salt Lake City, UT Native American Community Health Center <u>Physician</u>	October 2008 – November 2008
Power & Brown, Mesa, AZ <u>Physician</u>	November 2008 – May 2009
Med Quest Associates, Alpharetta, GA <u>Physician Radiology Coverage</u>	January 2008 – October 2008
Parker Medical Associates, P.C., Gilbert, AZ <u>Owner/Physician</u>	March 2006 – June 2009
New Beginnings Laser Therapy & Medispa, Gilbert, AZ <u>Medical Director</u>	March 2006 – June 2009

Laser Concepts of New Orleans, LLC, Metairie, LA <u>Medical Director</u>	November 2004 – December 2005
MMS Medical Research, LLC, Metairie, LA <u>Primary Investigator</u>	March 2004 – December 2005
Doctors Urgent Care of Slidell, Slidell, LA <u>Physician</u>	March 2003 – June 2004
Lakeside Family Practice, LLC, Metairie, LA <u>Owner/Physician</u>	July 2002 – December 2005
Correct Care Inc, Covington, LA <u>Emergency Room Physician</u>	January 2001 – March 2002
The Schumacher Group, Lafayette, LA <u>Emergency Room Physician</u>	August 2001 – January 2003

BOARD CERTIFICATIONS

Family Medicine	through 2028
Hospice & Palliative Care	through 2030

POST-GRADUATE TRAINING

East Jefferson General Hospital, Metairie, LA <u>Chief Resident</u>	2001
East Jefferson General Hospital, Metairie, LA <u>Family Practice Residency Program</u>	1999-2002

EDUCATION

St. Joseph University, Philadelphia, PA <u>MHA: Health Care Ethics Specialization</u>	2014
Louisiana State University, Baton Rouge, LA <u>Doctor of Medicine</u>	1999
Xavier University of New Orleans, New Orleans, LA <u>Bachelor of Science: Biology (Minor: Chemistry)</u>	1995

ACADEMIC APPOINTMENTS

Valley Health System – GMEC, Las Vegas, NV August 2021 - Present
Department of Family Medicine
Faculty

Kirk Kerkorian School of Medicine, UNLV, Las Vegas, NV July 2021 - Present
Clinical Assistant Professor

Touro University Nevada, Henderson, NV July 2018 – January 2020
College of Osteopathic Medicine
Adjunct Faculty Member

PROFESSIONAL LICENSURE

Nevada State Board of Medical Examiners March 2018 - Present
License Number: 17763

Arizona Medical Board, December 2005 - Present
License Number: 34880

PROFESSIONAL MEMBERSHIPS

American Academy of Family Physician
American Academy of Hospice and Palliative Care Medicine
NHPCO
Texas Academy of Palliative Medicine
Texas Medical State Society

COMMITTEE EXPERIENCE

Advanced Care Planning Committee, *Parkview Health* 2014 - 2017
Cancer Committee, *Parkview Health* 2016 - 2017
Comagine Health NV Community Board 2018 - Current
Ethics Committee, *Hendrick Medical Center*
Ethics Committee, *Parkview Health* 2014 - 2017
Executive Board, *Taylor Jones Haskell Callahan County Medical Society*
Finance Committee, *Abilene Diagnostic Center* 2010 - 2013
Fort Wayne Medical School Family Medicine/Palliative Care Preceptor
Hospital Re-Admission Committee, *Parkview Health* 2014 - 2017
IT/Compliance Peer Review, *Abilene Diagnostic Center* 2010 - 2013
Nevada State POLST Board Committee 2021 - Current

NHPCO Board	2022 - Current
NHPCO Education Committee	
Physician Leadership Committee, <i>Abilene Regional Medical Center</i>	2010 - 2013
Professional Physicians Sub Committee	
Southern Nevada Senior Law Program Board	2022 - Current

SPECIAL TRAINING

LEAN Six Sigma Black Belt, Las Vegas, NV

HONORS AND AWARDS

Top Doctors, Palliative Care 2021

RESEARCH EXPERIENCE

1. CVAH631DUS02 - Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP): A Multicenter, Randomized, Open-label, 2-Arm Parallel Group Study to Evaluate the Efficacy of Moderate Vs. Aggressive Antihypertensive Therapy with Diovan® and Diovan HCT® to Reduce Blood Pressure and Plasma hsCRP levels in Patients with Stage 2 Hypertension. 2004 – 2005.
2. HMR3647A/4019: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare Clinical Health Outcomes of Telithromycin versus Azithromycin in Outpatients with Community-Acquired Lower Respiratory Tract Infections. 2004 – 2005.
3. CCIB002FUS12 A Multicenter, Double-blind, Randomized, Parallel Group Study to Evaluate the Effects of Lotrel and Lotensin HCT on Albuminuria in Mild to Moderate Hypertensive Subjects with Type 2 Diabetes Mellitus. 2004 – 2005.
4. {Isis Pharmaceuticals} ISIS-2302-CS20-Phase 3 double-masked, placebo- controlled study of Alicaforfen (ISIS 2302) and antisense inhibitor of ICAM-1, for the treatment of patients with Active Crohn's Disease. January 2002 – December 2004.
5. {Abbott Laboratories} M02-403 – A multi-center, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody Adalimumab for the induction of clinical remission in subjects with Crohn's Disease. September 2002 – May 2004.

6. {GlaxoSmithKline} 49653/330 – A randomized, double-blind, placebo- controlled, parallel group study to assess the safety and efficacy of three dose levels of Rosiglitazone Maleate in the treatment of chronic Plaque Psoriasis. March 2003 – September 2004.
7. {Axcan Pharma} ASGELUC-02-03 – Clinical efficacy and safety of Mesalamine Rectal Gel vs. placebo in the treatment of mild to moderate Distal Ulcerative Colitis: A multicenter, double- blind, randomized, and parallel groups study. March 2003 – August 2004.
8. {Protein Design Labs} DAC-1008 – A phase II, randomized, double-blind, placebo- controlled, multi-center, dose-ranging study of intravenous Daclizumab in patients with moderate to severe Ulcerative Colitis. March 2003 – May 2004.
9. {Centocor} C0168T46 – A Randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of Infliximab in patients with active Ulcerative Colitis. March 2003 – December 2004.
10. {ALZA Corp.}C-2002-013 – A placebo-controlled, double-blind, randomized, parallel study of the efficacy and safety of Dapoxetine HCl in the treatment of Rapid Ejaculation. May 2003 – October 2004.
11. {AstraZeneca Pharmaceuticals LP} 4522US/0011 – A randomized, double-blind, placebo- controlled, multicenter, Phase III study of Rosuvastatin (Crestor 20mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-Cholesterol and elevated levels of C-Reactive Protein. June 2003 – December 2004.
12. {Vela Pharmaceuticals Inc.} VPI-TOFP-201 – A double-blind, randomized, placebo- controlled study of R-Tofisopam in outpatients with Irritable Bowel Syndrome. July 2003 – August 2004.
13. Laser Therapy in the Treatment of Addictions to Nicotine as Delivered by Tobacco Smoke. A pre- clinical phase 2 trial on the effectiveness of laser devices as an aid in the reduction of addictions to nicotine as delivered in tobacco smoke. 2004.
14. CCIB002I2301 ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) prospective, multinational, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension. 2004 – 2005.